Biotech firm argenx SE is making strides in the development of therapies for autoimmune diseases across the globe, with a presence in the US, the Netherlands, Belgium, Japan, Switzerland, Germany, France, Canada, the UK, and Italy. The firm's primary product candidate is efgartigimod, intended for the treatment of a range of conditions including immune thrombocytopenia and chronic inflammatory demyelinating polyneuropathy. The company is also pursuing development of other therapies such as ARGX-109 and ARGX-116, with emphasis on severe autoimmune conditions. Arguably most notable among the company's collaborations is its alliance with AbbVie S.À.R.L. and its strategic partnerships with Zai Lab Limited and LEO Pharma A/S. Founded in 2008, the firm is headquartered in the Dutch city of Amsterdam.
argenx SE's ticker is ARGX
The company's shares trade on the NASDAQ stock exchange
They are based in Ghent, Belgium
There are 501-1000 employees working at argenx SE
It is https://www.argenx.com/
argenx SE is in the Healthcare sector
argenx SE is in the Biotechnology industry
The following five companies are argenx SE's industry peers: